Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors

Based on research topic, choose the appropriate contact from the NOSI or the related announcement.

This opportunity is a Notice of Special Interest (NOSI) for research to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors.

Proposed projects must:

1. Focus on survivors of childhood cancers (diagnosed prior to the age of 19)
2. Address factors contributing to disparities in survivorship care and outcomes that extend beyond the individual (such as survivors, caregivers, and clinicians) level to include healthcare teams, healthcare systems, community, and policy-level factors
3. Include populations commonly experiencing disparities based on race or ethnicity, sex, sexual or gender minority status, insurance status, rural residence, socioeconomic disadvantage, or other demonstrated differences

Examples of projects may include, but are not limited to:

• Assess healthcare team, healthcare system, community, payer, and policy level factors or practices that result in inequities such as disparities in long-term follow-up care
• Develop and test novel methods for identifying barriers to survivorship care delivery using data elements available in the medical record, administrative datasets, surveys, and/or interviews
• Evaluate multilevel interventions that promote guideline-concordant survivorship care for childhood cancer survivors
• Develop and test multilevel interventions to mitigate barriers that contribute to disparities in health outcomes for childhood cancer survivors
• Characterize barriers to behavioral health, tobacco cessation, or alcohol reduction interventions for childhood cancer survivor populations that experience health disparities

Eligible applicants include:

• Higher education institutions
  • Public/state controlled institutions
  • Private institutions
• Nonprofit organizations
  • With 501(c)(3) status
  • Without 501(c)(3) status
  • Native American tribal organizations
  • Faith-based or community-based organizations
  • Regional organizations
• Governments
  • State
  • County
  • City or township
  • Special districts
  • Federally recognized Indian/Native American tribal governments
  • Indian/Native American tribal governments (other than federally recognized)
  • Eligible agencies of the federal government
  • U.S. territory or possession
• Other
  • Independent school districts
  • Public housing authorities
  • Indian housing authorities
  • Non-domestic entities and non-domestic components of U.S. entities
  • Small businesses
  • For-profit organizations

Funding amounts are based upon the guidance provided by the related announcements.

This is a NOSI that is attached to related NIH announcements:

• Funding Opportunity Announcement Number (FOA#) PAR-21-190
  Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
• FOA# PAR-21-035
  Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
• FOA# PAR-20-183
  NIH Research Project Grant (Parent R01 Clinical Trial Required)
• FOA# PAR-20-185
  NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• FOA# PAR-21-038
  Stephen I. Katz Early Stage Investigator Research Project Grant (Clinical Trial Not Allowed)
• FOA# PAR-21-341
  Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
• FOA# PAR-20-195
  NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• FOA# PAR-20-194
  NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
• FOA# PAR-20-052
  NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)
• FOA# PA-20-200
  NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
• FOA# PAR-20-077
  National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

Applicants should submit proposals to the related announcement and indicate that it is a response to the NOSI.

This NOSI expires on October 9, 2024.